The Role of Umbilical Cord Serum Therapy on Improvement of Corneal Epithelial Defect Following Diabetic Vitrectomy
Information source: Shahid Beheshti Medical University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Corneal Epithelial Defect
Intervention: conventional therapy plus umbilical cord serum eye drop (Drug); conventional therapy (Drug)
Phase: Phase 1
Status: Active, not recruiting
Sponsored by: Shahid Beheshti Medical University
Summary
80 diabetic patients underwent vitrectomy and had no history of Eye herpes infection,
Refractive surgery, Autoimmune disease, Immune deficiency will be randomized into two groups
(double blind)to evaluate the role of umbilical cord serum therapy on improvement of corneal
epithelial defect following diabetic vitrectomy. Both groups will take the conventional
medication including Chloramphenicol, Betamethasone, Cycloplegic eye drops besides the case
group will take umbilical cord serum eye drop in the eye operated. After surgery the corneal
epithelial defect will be measured by slit lamp.
Clinical Details
Official title: The Role of Umbilical Cord Serum Therapy on Improvement of Corneal Epithelial Defect Following Diabetic Vitrectomy
Study design: N/A
Primary outcome: measurement of corneal epithelial defect
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Diabetic patients with corneal epithelial defect following diabetic vitrectomy at
labbafinejad Hospital
Exclusion Criteria:
- Any history of Eye herpes infection, Refractive surgery, Autoimmune disease, Immune
deficiency
- Patients with one eye
- Use of any eye drops except Chloramphenicol, Betamethasone, Cycloplegic and contact
lens for corneal epithelial defect
Locations and Contacts
Ophthalmic Research Center, Tehran 166666, Iran, Islamic Republic of
Additional Information
Last updated: July 22, 2010
|
